A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.

Trial Profile

A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Dasatinib (Primary) ; Bevacizumab; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2014 According to ClinicalTrials.gov record planned end date changed from 1 May 2014 to 1 Oct 2014.
    • 06 Dec 2011 Actual patients number (22) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top